

Investigational Medicinal Product	Phase 1	Phase 2	Phase 3	Disease Area of Research
BGB-24714 (SMAC Mimetic) +/- Chemotherapy				Advanced solid tumors
BGB-3245 (BRAF inhibitor)				Advanced solid tumors with BRAF mutations
BGB-B167 (CEA-4-1BB bispecific antibody) +/- Tislelizumab (anti-PD-1)				Advanced solid tumors
Lifirafenib (RAF inhibitor) + Mirdametinib (MEK inhibitor)				Advanced solid tumors
Ociperlimab (anti-TIGIT) + Tislelizumab				1L PD-L1 high advanced NSCLC
				2L PD-L1+ advanced ESCC
				2L+ cervical cancer
				Advanced solid tumors
Ociperlimab + Tislelizumab + BAT1706 (anti-VEGF)				1L HCC
Ociperlimab + Tislelizumab + Chemotherapy				1L NSCLC
Ociperlimab + Tislelizumab + Concurrent Chemoradiotherapy				Previously untreated, stage III unresectable NSCLC
				Previously untreated LS-SCLC
Pamiparib (PARP 1/2 inhibitor)				2L/3L maintenance platinum-sensitive OC
				1L maintenance platinum-sensitive GC
				Advanced OC and TNBC
Pamiparib + Temozolomide				Advanced solid tumors
Tislelizumab				2L advanced ESCC
				1L HCC
				2L/3L NSCLC
				1L MSI-H or dMMR CRC
				Previously treated advanced MSI-high or dMMR solid tumors
Tislelizumab +/- Surzebiclimab (anti-TIM-3) +/- LBL-007 (anti-LAG-3)				Advanced solid tumors
Tislelizumab +/- Ociperlimab +/- LBL-007				Resectable stage II/IIIA NSCLC
Tislelizumab + BGB-A445 (anti-OX40)				Advanced solid tumors
Tislelizumab + BGB-10188 (PI3Kδ inhibitor)				Advanced solid tumors
Tislelizumab + BGB-15025 (HPK1 inhibitor)				Advanced solid tumors

Safety and efficacy have not been established for investigational products and/or uses.

BC, breast cancer; BRAF, B-Raf proto-oncogene; CEA, carcinoembryonic antigen; CRC, colorectal cancer; dMMR, mismatch repair deficient; ESCC, esophageal squamous cell carcinoma; GC, gastric cancer; HCC, hepatocellular carcinoma; HPK1, hematopoietic progenitor kinase 1; LAG-3, lymphocyte-activation gene 3; LS-SCLC, limited-stage small cell lung cancer; MSI, microsatellite instability; MSI-H, microsatellite instability-high; NSCLC, non-small cell lung cancer; OC, ovarian cancer; PD-L1: programmed death ligand-1; PIK3δ, phosphoinositide 3-kinase delta; SMAC, Second Mitochondrial-derived Activator of Caspases; TIGIT: T-cell immunoreceptor with Ig and ITIM domains; TIM-3, T cell immunoglobulin and mucin domain-containing protein 3; TNBC, triple-negative breast cancer; VEGF, vascular endothelial growth factor.



Investigational Medicinal Product	Phase 1	Phase 2	Phase 3	Disease Area of Research
Tislelizumab + Chemoradiotherapy				Localized ESCC
Tislelizumab + Chemotherapy/ Chemoradiotherapy				Resectable ESCC
Tislelizumab + Chemotherapy				1L advanced ESCC
				1L GC/GEJC
				Resectable stage II or IIIA NSCLC
				1L advanced nasopharyngeal cancer
				1L squamous NSCLC
				1L non-squamous NSCLC
				1L advanced UBC
				1L ES-SCLC
Tislelizumab + DKN-01 (anti-DKK1) + Chemotherapy				1L/2L GC/GEJC
Tislelizumab + Fruquintinib (VEGFR inhibitor)				Advanced GC/GEJC, CRC, and NSCLC
				Advanced triple negative BC, EC, and CRC
Tislelizumab + Lenvatinib (VEGFR kinase inhibitor)				1L HCC
				Advanced solid tumors
Tislelizumab + Sitravatinib (multikinase inhibitor)				Advanced NSCLC after anti-PD-(L)1 therapy
				Advanced GC/GEJC/HCC
				HCC post resection
				Advanced ESCC after anti-PD-(L)1 therapy
				Advanced solid tumors
Tislelizumab + Surufatinib (VEGFR, FGFR, CSF-1R inhibitor)				Advanced solid tumors
Zanidatamab (anti-HER2 bispecific antibody)				2L+ HER2+ BTC
Zanidatamab + Chemotherapy +/- Tislelizumab				1L HER2+ BC and 1L HER2+ GC/GEJC
Zanidatamab + Chemotherapy +/- Tislelizumab				1L HER2+ advanced/metastatic GC/EC